PTC Therapeutics, Inc. (PTCT) EPS Estimated At $-0.87

October 13, 2017 - By Darrin Black

 PTC Therapeutics, Inc. (PTCT) EPS Estimated At $ 0.87
Investors sentiment decreased to 0.92 in Q2 2017. Its down 0.24, from 1.16 in 2017Q1. It dropped, as 17 investors sold PTC Therapeutics, Inc. shares while 34 reduced holdings. 17 funds opened positions while 30 raised stakes. 31.07 million shares or 6.35% more from 29.21 million shares in 2017Q1 were reported.
Aqr Mngmt Limited Liability owns 50,554 shares. Great West Life Assurance Can has 4,580 shares. Fisher Asset Mngmt Ltd reported 89,642 shares. Proshare Advisors Limited Liability stated it has 24,115 shares. Royal Bancorp Of Canada invested in 0% or 763 shares. Great Point Prtnrs Ltd Liability owns 1.90M shares. State Board Of Administration Of Florida Retirement has invested 0% in PTC Therapeutics, Inc. (NASDAQ:PTCT). Zurcher Kantonalbank (Zurich Cantonalbank) invested 0% of its portfolio in PTC Therapeutics, Inc. (NASDAQ:PTCT). Amer International Group Inc Inc accumulated 20,682 shares. Manufacturers Life Ins Communications The holds 0% of its portfolio in PTC Therapeutics, Inc. (NASDAQ:PTCT) for 26,191 shares. 52,779 are owned by Parametric Limited Com. Venbio Select Advisor Ltd Liability Corporation has 0.28% invested in PTC Therapeutics, Inc. (NASDAQ:PTCT). Blackrock Inc reported 0% in PTC Therapeutics, Inc. (NASDAQ:PTCT). Canada Pension Plan Board invested in 40,600 shares. Quantitative Invest Mngmt Ltd Com reported 117,100 shares.

Since May 23, 2017, it had 1 insider purchase, and 0 sales for $337,230 activity.

Analysts await PTC Therapeutics, Inc. (NASDAQ:PTCT) to report earnings on November, 1. They expect $-0.87 EPS, up 15.53 % or $0.16 from last year’s $-1.03 per share. After $-0.44 actual EPS reported by PTC Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 97.73 % negative EPS growth. The stock increased 0.17% or $0.03 during the last trading session, reaching $17.86. About 528,373 shares traded. PTC Therapeutics, Inc. (NASDAQ:PTCT) has risen 104.51% since October 13, 2016 and is uptrending. It has outperformed by 87.81% the S&P500.

PTC Therapeutics, Inc. (NASDAQ:PTCT) Ratings Coverage

Among 11 analysts covering PTC Therapeutics (NASDAQ:PTCT), 4 have Buy rating, 2 Sell and 5 Hold. Therefore 36% are positive. PTC Therapeutics had 30 analyst reports since July 31, 2015 according to SRatingsIntel. The stock of PTC Therapeutics, Inc. (NASDAQ:PTCT) has “Underperform” rating given on Wednesday, November 25 by Jefferies. The rating was upgraded by Credit Suisse to “Outperform” on Monday, November 14. Citigroup upgraded the stock to “Buy” rating in Friday, November 11 report. JP Morgan downgraded the stock to “Neutral” rating in Tuesday, February 23 report. The firm has “Hold” rating given on Tuesday, September 26 by J.P. Morgan. The firm has “Sector Perform” rating by RBC Capital Markets given on Friday, November 11. The firm earned “Neutral” rating on Tuesday, July 26 by Credit Suisse. The stock of PTC Therapeutics, Inc. (NASDAQ:PTCT) has “Outperform” rating given on Friday, October 16 by Oppenheimer. The firm has “Sell” rating given on Monday, October 9 by J.P. Morgan. RBC Capital Markets maintained it with “Outperform” rating and $56 target in Friday, October 16 report.

PTC Therapeutics, Inc. is a biopharmaceutical company. The company has market cap of $739.21 million. The Firm is focused on the discovery, development and commercialization of medicines using its expertise in ribonucleic acid biology. It currently has negative earnings. The Company’s product pipeline includes Ataluren (Translarna), PTC596 and RG7916.

More notable recent PTC Therapeutics, Inc. (NASDAQ:PTCT) news were published by: Fool.com which released: “The Unusual Reason PTC Therapeutics, Inc. Is Bouncing Back Today” on September 29, 2017, also Benzinga.com with their article: “US Approval Of PTC Therapeutics’ Translarna ‘Remains Unlikely'” published on September 29, 2017, Nasdaq.com published: “PTC Therapeutics, Inc. (PTCT) in Focus: Stock Moves 14.6% Higher” on October 02, 2017. More interesting news about PTC Therapeutics, Inc. (NASDAQ:PTCT) were released by: Fool.com and their article: “Here’s Why PTC Therapeutics, Inc. Is Slipping Today” published on September 26, 2017 as well as Prnewswire.com‘s news article titled: “Long-Term PTC Investors: Johnson Fistel Initiates Investigation of PTC …” with publication date: September 27, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.